Miquel Granell - Concepedia

Author

Miquel Granell

Also Known As

Gemma Azaceta, Juan Alfonso Soler, M Granell, M. Granell, M. Granell Gorrochategui, Miquel Granell, Miquel Granell Gorrochategui

Publications

1.8K

Citations

H-Index

Concepts

All Affiliations

Hospital de Sant Pau Hospital Clínic de Barcelona Consorci Institut D'Investigacions Biomediques August Pi I Sunyer Institut Català d'Oncologia Complejo Hospitalario de Salamanca

About

Miquel Granell is an author at Hospital de Sant Pau specializing in medicine, transplantation, and immunology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	8	8	494
2	Immunology	5	5	396
3	Health Sciences	4	4	119
4	Marrow Transplantation	2	2	78
5	Cellular Therapies	1	1	11

Miquel Granell

Publications

1.6K

Citations

H-Index

Page 1

	Year	Citations
Superiority of bortezomib, thalidomide, and dexamethasone (VTD) as induction pretransplantation therapy in multiple myeloma: a randomized phase 3 PETHEMA/GEM study Laura Rosiñol, Albert Oriol, Ana Isabel Teruel, Blood	2012	485
Ibrutinib for patients with rituximab-refractory Waldenström's macroglobulinaemia (iNNOVATE): an open-label substudy of an international, multicentre, phase 3 trial Meletios Α. Dimopoulos, Judith Trotman, Alessandra Tedeschi, The Lancet Oncology Open-label SubstudyImmunologyClinical TrialsRituximab-refractory WaldenströmImmunotherapy	2016	231
Maintenance therapy with bortezomib plus thalidomide or bortezomib plus prednisone in elderly multiple myeloma patients included in the GEM2005MAS65 trial María‐Victoria Mateos, Albert Oriol, Joaquín Martínez‐López, Blood	2012	143
Prognostic impact of circulating plasma cells in patients with multiple myeloma: implications for plasma cell leukemia definition Miquel Granell, Xavier Calvo, Antoni García‐Guiñón, Haematologica	2017	123
GEM2005 trial update comparing VMP/VTP as induction in elderly multiple myeloma patients: do we still need alkylators? María‐Victoria Mateos, Albert Oriol, Joaquín Martínez‐López, Blood	2014	102
Zanubrutinib for the treatment of MYD88 wild-type Waldenström macroglobulinemia: a substudy of the phase 3 ASPEN trial Meletios Α. Dimopoulos, Ramón García‐Sánz, Hui‐Peng Lee, Blood Advances Hematological MalignancyOncologyAspen TrialMalignant Blood DisorderImmunology	2020	76
Bortezomib and thalidomide maintenance after stem cell transplantation for multiple myeloma: a PETHEMA/GEM trial Laura Rosiñol, Albert Oriol, Ana Isabel Teruel, Leukemia Hematological MalignancyTransplantationMarrow TransplantationOncologyPethema/gem Trial	2017	67
Impact of Epstein Barr virus-related complications after high-risk allo-SCT in the era of pre-emptive rituximab Irene García‐Cadenas, Nerea Castillo, Rodrigo Martino, Bone Marrow Transplantation Lymphoid NeoplasiaHigh-risk Allo-sctAutoimmune DiseaseImmunodeficienciesImmunology	2015	55
A phase II trial of lenalidomide, dexamethasone and cyclophosphamide for newly diagnosed patients with systemic immunoglobulin light chain amyloidosis María Teresa Cibeira, Albert Oriol, Juan José Lahuerta, British Journal of Haematology	2015	49
Maintenance Therapy After Stem-Cell Transplantation for Multiple Myeloma with Bortezomib/Thalidomide Vs. Thalidomide Vs. alfa2b-Interferon: Final Results of a Phase III Pethema/GEM Randomized Trial Laura Rosiñnol, Albert Oriol, Ana Isabel Teruel, Blood	2012	28

Page 1